References
- Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol. 2011;49(4):277–283. doi: 10.3109/15563650.2011.582471.
- Cole JB, Arens AM, Laes JR, et al. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am J Emerg Med. 2018;36(10):1817–1824. doi: 10.1016/j.ajem.2018.02.004.
- Mégarbane B, Deye N, Bloch V, et al. Intentional overdose with insulin: prognostic factors and toxicokinetic/toxicodynamic profiles. Crit Care. 2007;11(5):R115. doi: 10.1186/cc6168.
- Corcoran JN, Jacoby KJ, Olives TD, et al. Persistent hyperinsulinemia following high-dose insulin therapy: a case report. J Med Toxicol. 2020;16(4):465–469. doi: 10.1007/s13181-020-00796-2.
- Roberts DM, Hughes HK, Haber PS, et al. Variability in insulin pharmacokinetics following high-dose insulin therapy. Clin Toxicol. 2022;60(3):389–391. doi: 10.1080/15563650.2021.1967372.
- Arnolds S, Kuglin B, Kapitza C, et al. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64(10):1415–1424. doi: 10.1111/j.1742-1241.2010.02470.x.
- Mincu I, Ionescu-Tirgoviste C. Half-life and hypoglycemic effect of intravenous insulin in patients with diabetic ketoacidosis. Med Interne. 1980;18(3):287–292.
- Bayly GR, Ferner RE. Persistent insulin secretion after insulin overdose in a non-diabetic patient. Lancet. 1993;341(8841):370. doi: 10.1016/0140-6736(93)90168-g.
- Hamzić J, Raos D, Radulović B. High-dose insulin euglycemic therapy. Acta Clin Croat. 2022;61(Suppl 1):73–77.
- Cole JB, Lee SC, Prekker ME, et al. Vasodilation in patients with calcium channel blocker poisoning treated with high-dose insulin: a comparison of amlodipine versus non-dihydropyridines. Clin Toxicol. 2022;60(11):1205–1213. doi: 10.1080/15563650.2022.2131565.